DiscGenics

Description

DiscGenics is a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.

Founders:

Flagg Flanagan

Company Size:

11-50 

TechBuzz Articles:

DiscGenics Raises $50 Million for Novel Back Pain Treatment, Mark Tullis, October 21st, 2020

Buzzworthy Mentions:

DiscGenics Announces Positive Interim Data on Clinical Trial of IDCT Therapy, March 4th, 2022

DiscGenics Completes Enrollment in Japanese Study, April 30th, 2021